NCCN adds Nuvation Bio's ROS1 inhibitor IBTROZI (taletrectinib) as systemic therapy in CNS Cancers guidelines for ROS1-positive NSCLC brain metastases
https://finviz.com/quote.ashx?t=NUVB&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.